Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists

Psychedelic substances produce a wide range of perceptual, emotional and cognitive alterations that are collectively referred to as psychedelic experiences. Earlier research and recent ‘‘renaissance’’ studies suggest these experiences can yield important therapeutic effects — for example reductions in depression, anxiety and addictive behaviours — but they may also be challenging and lead to adverse outcomes such as acute distress, prolonged perceptual changes (HPPD), traumatic-like symptoms or functional impairment. The effects of psychedelics reflect both pharmacology and extra-pharmacological factors (set and setting), and benefits observed after single exposures often attenuate without supportive follow-up. Greń and colleagues identify a gap between the growing prevalence of psychedelic use and the readiness of mental health professionals to support people after such experiences. Existing graduate training in psychiatry, psychology and psychotherapy seldom prepares clinicians to address psychedelic-specific content or consequences, and few publicly available, clinician-oriented guidelines on psychedelic integration exist. To fill this gap, the authors report an international, bottom-up project that aimed to develop comprehensive theoretical and practical guidelines for psychedelic integration intended for a broad range of mental health specialists.

The guidelines were produced by an international team convened under the project ‘‘An international network of therapists for integration of psychedelic experiences,’’ funded by the Visegrad Fund. Team members represented clinical and research institutions in the Czech Republic, Poland, Hungary and Slovakia, with support from a German partner. Participants included psychotherapists from humanistic, psychodynamic and depth approaches, a clinical psychiatrist/neuroscientist, an addiction therapist and harm-reduction practitioners. The project combined expert roundtable deliberations with a literature review to reach consensus on the scope and content of the guidelines. Initial in-person roundtable discussions were used to define key terms (for example, ‘‘psychedelic integration’’), to map timelines for integration practice (early and late stages) and to divide work into four drafting subgroups (early theoretical, early practical, late theoretical, late practical). Drafts from the subgroups were compiled and refined in a second in-person meeting until consensus was reached. Subsequent iterative refinements occurred online during the COVID-19 pandemic, producing a final guidelines document that informed the present manuscript. A comprehensive literature review complemented the consensus work. The authors searched PubMed, Web of Science, Scopus and Google Scholar through 1 September 2020 using the keywords "psychedelic integration" and "psychedelic therapy." An attempt at a restricted systematic review returned only one peer-reviewed article specifically addressing integration, so the team broadened the review to include clinical trial manuals and books while excluding preprints, dissertations and other grey literature. A further search updating the review was completed by 25 August 2022 and used to incorporate several more recent positions. The development process was therefore qualitative and consensus-driven rather than hypothesis-testing; the final recommendations combine literature synthesis with the expert team's practical experience.

The central outputs are a clinician-friendly definition of psychedelic integration, a simple two-stage model for organising integration practice, and a compendium of theoretical considerations and practical interventions. Greń and colleagues define psychedelic integration as any conscious, informed attempt in clinical or therapeutic settings to process the content and consequences of a psychedelic experience so that its relevant outcomes can be implemented into everyday life. This definition aligns with recent literature that frames integration as a bridge between the psychedelic event and daily living, ideally beginning before substance use and continuing thereafter. The proposed two-stage model organises integration temporally into an early stage and a later stage. The early stage is brief, typically up to approximately five one-hour sessions, and emphasises immediate support: establishing therapeutic rapport, screening for contraindications and urgent medical or psychiatric needs, psychoeducation and normalisation, basic stabilisation and clarification of client goals. Priority is placed on treating acute or distressing psychedelic-related consequences. The later stage targets deeper, longer-term work to consolidate insights and support behavioural change; it may employ more specific psychotherapeutic modalities or transition into routine psychotherapy. The authors note that for many clients early-stage interventions will suffice, while others will require extended support. Guideline aims are framed pragmatically as either minimising harms or maximising benefits, depending on client needs. Basic interventions recommended for the early stage include ensuring client safety and confidentiality, co-determining work direction and priorities, gathering medical history and screening, and setting up a formal structure for sessions (frequency, duration, costs). The team emphasise individualised practice due to the ‘‘noetic’’ quality of psychedelic experiences and recommend assessing factors that condition differential responses (for example prior mental health, personality traits, context of use). Practical techniques described include resource-oriented work (identifying and mobilising clients' inner and external supports), calming and grounding exercises (body awareness, grounding through nature, breathwork, mindful walking), psychoeducation and normalisation about psychedelic effects, and structured methods to analyse and organise the remembered experience. Concrete tools for organising experiences include timelines, emotion graphs (emotion intensity plotted over time), body-centred mapping and expressive modalities (drawing, journaling, movement). The authors caution that heightened suggestibility in the afterglow period (often lasting about 6–8 weeks) increases neuroplasticity but also requires care to avoid imposing dogmatic interventions without consent. For clients needing second-stage work, the guidelines survey existing models and psychotherapeutic approaches that can be adapted for integration. The authors summarise contemporary models (many emerging since 2017) as broadly holistic, addressing psychological, somatic, spiritual and community domains, or focused on mind and behavioural change. Specific approaches they discuss as potentially useful include Acceptance and Commitment Therapy (ACT) — protocols pair ACT principles with elicitation of the psychedelic narrative and value-directed committed action — mindfulness-based interventions, Internal Family Systems (IFS) to dialog with ‘‘parts’’ accessed in the experience, process-oriented psychotherapy and Gestalt techniques (such as empty-chair work), and psychodynamic or Jungian depth approaches that treat psychedelic material like significant dreams and explore symbolic content and archetypal material. Trauma-like reactions following challenging psychedelic sessions are addressed; the authors recommend treating such presentations in line with trauma-informed care and established evidence-based treatments for PTSD where appropriate (for example cognitive processing, prolonged exposure or EMDR), while noting the lack of direct evidence specifically for psychedelics-induced trauma symptoms. Group-based formats such as sharing circles are also presented as commonly used in retreat and ceremonial contexts, and potentially useful for integration when well facilitated. The guidelines also cover theoretical issues related to mechanisms and practice: classical psychedelics act primarily via serotonin 5-HT2A receptor agonism and induce alterations in brain network connectivity, increased neuroplasticity and an afterglow characterised by increased sensitivity, openness and suggestibility. Non-classical substances (for example MDMA, ketamine) have different mechanisms and clinical profiles. The authors emphasise the importance of set and setting, harm-reduction framing for work when substances are illegal, and the ongoing debate about whether therapists should have their own psychedelic experiences; they regard personal experience as informative but not mandatory and note legal, ethical and practical constraints. Finally, the literature search process itself yielded relatively few academic sources specifically dedicated to integration at the time of the initial review, prompting reliance on clinical manuals, books and emerging literature. The final document is therefore a synthesis of expert consensus plus available evidence rather than the outcome of a large-scale empirical study.

Greń and colleagues interpret their guideline project as a pragmatic response to an expanding need: rising public interest and use of psychedelics, together with limited clinician training, create a gap in post-experience care that integration practice can address. They position their work as a clinician-oriented synthesis that combines theoretical foundations (mechanisms, set and setting, afterglow) with a practical, time-structured model and a menu of interventions drawn from established psychotherapies and community practices. The authors situate their recommendations within ongoing debates: they acknowledge tensions between non-directive, ‘‘inner-healer’’ orientations and more directive, theory-driven therapeutic interventions, and propose that both approaches have roles depending on stage and client need. They also highlight ethical and legal complexities of offering integration in contexts where psychedelics are illegal, and advocate a harm-reduction framework that neither pathologises nor promotes use, but focuses on client safety and informed decision-making. Key limitations noted by the authors include the nascency of the field and the uneven evidence base for many integration practices. Several of the proposed methods derive from existing psychotherapies or indigenous traditions, and the authors caution that some practices may be context-dependent or require specialist training and supervision. They explicitly state that the effectiveness of many listed interventions as applied specifically to psychedelic integration remains unknown and that some modalities (for example trauma-focused treatments) require credentialled practitioners. Implications discussed by the authors include the need for expanded training, certification pathways and multi-university programmes to prepare clinicians for integration work, and for further research evaluating integration interventions and models. They hope the guidelines will support clinicians in reducing harms and consolidating benefits as psychedelics become more prominent in research and public life, while recognising that the guidance is an early effort in a rapidly evolving field.

The authors conclude that psychedelic integration is an increasingly important clinical competency given rising psychedelic use and the limited preparedness of mental health professionals. Their consensus-based guidelines offer a definition of integration, a two-stage time model, theoretical background on mechanisms and set-and-setting, and a catalogue of basic and specific interventions drawn from multiple psychotherapeutic traditions and community practices. Greń and colleagues present this synthesis as a clinician-friendly resource intended to help practitioners navigate both the potential benefits and risks of psychedelic experiences while calling for further training, research and careful, context-aware application of the recommendations.